< Back to Results
A Phase 3, Randomized, Open-Label, Comparative Study of DOXIL/CAELYX Versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyUnique Dataset IDOvarian_Johnson_1997_139ClinicalTrial.gov IDSTUDY_SEQUUS-30-49
Clinical Trial Title
A Phase 3, Randomized, Open-Label, Comparative Study of DOXIL/CAELYX Versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Trial Summary and Conditions
This was a Phase 3, parallel-group, randomized, multicenter, open-label, active-controlled study of women with epithelial ovarian carcinoma whose disease did not respond to or recurred after treatment with first-line chemotherapy with a platinum-based regimen. They had measurable disease and a Karnofsky performance status (KPS) of 60% or higher. Subjects received either a 1-hour i.v. infusion of DOXIL, 50 mg/m2 every 4 weeks, or topotecan, 1.5 mg/m2 per day as a 30-minute i.v. infusion for 5 consecutive days, repeated every 3 weeks. The dose of DOXIL used (50 mg/m2 via 1-hour i.v. infusion every 4 weeks) was selected on the basis of the results of Phase 1 and Phase 2 studies, which indicated that this dose had meaningful clinical activity and was well tolerated. Topotecan was administered at the FDA-approved dose and frequency for treatment of ovarian cancer. To obtain 370 evaluable subjects, up to 460 subjects were to have been enrolled in the study. Subjects were randomized to treatment in a 1:1 ratio stratified by platinum sensitivity and the presence or absence of bulky disease. According to the standards of care for this patient population at many participating sites, subjects could discontinue study treatment and be considered to have completed the protocol at the discretion of the investigator or subject after 6 months (6 cycles of DOXIL, 8 cycles of topotecan). Subjects with ongoing clinical benefit were able to continue study drug until disease progression upon approval of the sponsor. All randomized subjects who met enrollment criteria and received at least 2 cycles of study drug were considered evaluable for efficacy. Subjects who withdrew from the study were not replaced.
Control arm (Topotecan HCl) data files include analysis data on safety, efficacy, demographic, and baseline disease characteristics.
The primary objective of this study was to compare the efficacy and safety of DOXIL to those of topotecan in subjects with epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy. It was designed as a non-inferiority study. The objective of the post-study long-term follow-up analysis is to compare DOXIL versus topotecan HCl in terms of survival and PFS when approximately 90% of subjects have either died or are lost to follow-up.
The primary efficacy endpoint of this study was overall survival time defined as the time from the start of study drug administration to death. The secondary efficacy endpoint of this study was progression-free survival defined as the time from the first day of study drug dosing to the documented disease progression or death due to any cause while the subject was on study or during the long-term follow-up period.
To gain access to the data and analytic tools click here.
DATA DICTIONARY: DataDef_OVC_30_49.xls
DATA (COMPARATOR ARM): Datasets_OVC_30_49.zip